Karuna Therapeutics, Inc. - Common Stock (NQ:KRTX)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Karuna Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

December 22, 2023

Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.

Via Benzinga

S&P 500, Nasdaq 100 Aim For 8th Week Of Gains As Fed's Inflation Gauge Cools: What's Driving Markets Friday? ↗

December 22, 2023

The S&P 500 and Nasdaq 100 indices are on the verge of achieving an impressive eight consecutive weeks of gains following a more significant decline than expected in the Federal Reserve’s favored...

Via Benzinga

Topics Economy Stocks

Karuna Therapeutics Inc. (NASDAQ: KRTX) is a Leading Gainer in 12/22 Morning Trading

December 22, 2023

Via Investor Brand Network

Where Karuna Therapeutics Stands With Analysts ↗

December 12, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

December 22, 2023

Via Benzinga

Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review ↗

December 22, 2023

Despite a Wednesday tumble, the major indexes are right at 2023 highs.

Via Investor's Business Daily

Gold Moves Higher; US Consumer Sentiment Improves In December ↗

December 22, 2023

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Friday. The Dow traded up 0.16% to 37,465.58 while the NASDAQ rose 0.28% to 15,005.25. The S&P 500...

Via Benzinga

Topics Stocks

The Latest Analyst Ratings for Karuna Therapeutics ↗

November 20, 2023

Via Benzinga

Analyst Expectations for Karuna Therapeutics's Future ↗

November 03, 2023

Via Benzinga

With Karuna Therapeutics $14B Deal, Bristol Myers Is Serious For Re-Establishing Its Neurology Portfolio: Analyst ↗

December 22, 2023

Earlier Friday, Bristol Myers Squibb & Co (NYSE: BMY) agreed to acquire Karuna Therapeutics Inc (NASDAQ: KRTX) for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 bill

Via Benzinga

Karuna Therapeutics Jumps Following Takeover By Bristol Myers, Joins Rocket Lab USA, Altair Engineering And Other Big Stocks Moving Higher On Friday ↗

December 22, 2023

U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. (NASDAQ: KRTX) rose sharply during Friday’s session following acquisition...

Via Benzinga

Topics Stocks

Health Care Company Bristol-Myers Squibb Announces Merger With Karuna Therapeutics ↗

December 22, 2023

Via Benzinga

Dow Rises 50 Points; Fed's Preferred Inflation Gauge Cools In November ↗

December 22, 2023

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Friday. Following the market opening Friday, the Dow traded up 0.14% to 37,458.12 while the NASDAQ rose...

Via Benzinga

Topics Economy Stocks

Bristol Myers Squibb Scoops Up Schizophrenia Player Karuna Therapeutics In Massive $14B Deal ↗

December 22, 2023

On Friday, Bristol Myers Squibb & Co (NYSE: BMY) agreed to acquire Karuna Therapeutics Inc (NASDAQ: KRTX) for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion n

Via Benzinga

Premarket Moves: Nike Dips 11%, Karuna Therapeutics Soars 48% ↗

December 22, 2023

Friday has seen several stocks make notable moves ahead of the market opening, with Nike (NKE) and Karuna Therapeutics (KRTX) capturing the most attention.

Via Talk Markets

Karuna Stock Soars On Bristol Myers' $14 Billion Takeover ↗

December 22, 2023

Karuna is working on treatments for schizophrenia and Alzheimer's disease psychosis.

Via Investor's Business Daily

KRTX STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Karuna Therapeutics, Inc. Is Fair to Shareholders

December 22, 2023

From Halper Sadeh LLC

Via Business Wire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 22, 2023

Via Benzinga

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics

December 22, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia

December 14, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia

November 29, 2023

From PureTech Health plc

Via Business Wire

Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia

November 29, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Karuna Therapeutics Says Its Antipsychotic Candidate Shows Favorable Cardiovascular Safety Profile In Schizophrenia Patients ↗

November 17, 2023

Karuna Therapeutics Inc (NASDAQ: KRTX) released results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of KarXT (xanomeline-trospium) on 24-hour ambulatory blood...

Via Benzinga

Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia

November 16, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates

November 02, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress

November 01, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Karuna Therapeutics to Present at Upcoming Investor Conferences

November 01, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Karuna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023

October 19, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) Congress

October 04, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Karuna Takes A Big Step In Schizophrenia Treatment. Shares Jump Higher. ↗

September 28, 2023

Karuna Therapeutics says it could have the first new mechanism for schizophrenia treatment in decades.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.